news Releases

Aug 27, 2018
Aequus Reports 5th Consecutive Quarter of Revenue Growth
Aug 10, 2018
Aequus Closes Balance of $775,000 Equity Financing
Aug 09, 2018
Aequus Announces Fully-subscribed $775,000 Equity Financing
Jul 31, 2018
Aequus Announces Closing of $800,000 Equity Financing
Jul 24, 2018
Issuance of Stock Options
Jul 23, 2018
Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund
Jul 19, 2018
Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch
Jul 16, 2018
Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada
Jul 13, 2018
Aequus Announces New Independent Director to its Board
Jun 20, 2018
Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch
Jun 18, 2018
Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System
May 31, 2018
Aequus Provides First Quarter 2018 Financial and Corporate Highlights
May 16, 2018
Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018
May 03, 2018
Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch
Apr 27, 2018
Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth
Apr 26, 2018
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018
Apr 17, 2018
Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program
Apr 12, 2018
Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio
Mar 19, 2018
Aequus Expands Market in Quebec for Tacrolimus IR
Mar 07, 2018
FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch
Mar 05, 2018
Aequus and EHave enter into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
Jan 31, 2018
Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch
Jan 25, 2018
Aequus Announces Change to Proposed $300,000 Equity Financing
Jan 11, 2018
CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders
Jan 11, 2018
Aequus Announces Proposed $300,000 Equity Financing
Dec 08, 2017
Aequus announces the issuance of stock options
Nov 29, 2017
Aequus Provides Third Quarter 2017 Operational Highlights
Nov 16, 2017
Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole
Oct 10, 2017
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole
Sep 07, 2017
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch
Aug 29, 2017
Aequus Provides Second Quarter 2017 Operational Highlights
Aug 24, 2017
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole
Aug 17, 2017
Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000
Aug 01, 2017
Aequus and Scientus Agree to Terms for a Medical Cannabis Commercial Supply and Product Development Collaboration
Jul 05, 2017
Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch
Jun 15, 2017
Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch
Jun 13, 2017
Santen and Aequus Enter Into a Commercial Collaboration in Canada
Jun 12, 2017
Aequus Approves Advance Notice Policy
Jun 01, 2017
Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics
May 30, 2017
Aequus Provides First Quarter 2017 Financial Highlights
May 15, 2017
Aequus Validates Need for Improved Delivery Methods of Medical Cannabis
May 01, 2017
Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights
Apr 05, 2017
Aequus Launches Medical Cannabis Physician Research in US and Canada
Apr 03, 2017
Aequus Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch
Mar 13, 2017
Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option
Mar 03, 2017
Aequus Announces Upsizing of Previously Announced Bought Deal of Units to $4.5 Million
Mar 02, 2017
Aequus Announces $3 Million Bought Deal Financing
Mar 02, 2017
Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders
Feb 14, 2017
Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch
Feb 01, 2017
Aequus Receives Non-Dilutive Funding from the Government of Canada to Support Aripiprazole Patch Development
Jan 09, 2017
Aequus Initiates Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch
Dec 01, 2016
Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba
Nov 30, 2016
Aequus Provides Q3 2016 Financial Highlights with Substantial Increase in Quarter over Quarter Revenues
Nov 17, 2016
Aequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program
Oct 17, 2016
Aequus Advances Clinical Development of Transdermal Aripiprazole Patch
Oct 03, 2016
Aequus Partners with Camargo to Support US Regulatory Strategy for Development Programs
Sep 29, 2016
Aequus Obtains Ontario Provincial Listing for Vistitan™
Sep 13, 2016
Aequus Closes Financing for Gross Proceeds of C$2,743,920
Sep 06, 2016
Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing
Aug 30, 2016
Aequus Provides Corporate Update on Commercial and Development Programs
Aug 05, 2016
Aequus Announces Advancement of Anti-Nausea Transdermal Extended-Release Patent Application
Jul 29, 2016
Aequus Announces Advancement of Clobazam Transdermal Patent Application
Jul 22, 2016
Aequus appoints Ann Fehr as Chief Financial Officer
May 02, 2016
Aequus Announces Stock Option Grant
Apr 28, 2016
Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN™ in Canada
Apr 26, 2016
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference
Feb 26, 2016
Aequus Awarded Growth Stage Life Sciences Company of the Year
Feb 16, 2016
Aequus Licenses Canadian Commercialization Rights to Trokendi XR® and Oxtellar XR® from Supernus
Feb 04, 2016
Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
Jan 18, 2016
Aequus Pharmaceuticals to Present at Noble Capital Markets’ Investor Conference
Jan 12, 2016
Aequus Closes Previously Announced Equity Financings
Jan 07, 2016
Aequus Announces Proposed Equity Financings of Up to C$2,750,000
Dec 14, 2015
Aequus Announces Completion of Dosing in Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
Dec 02, 2015
Aequus Pharmaceuticals Initiates Promotional Efforts for Transplant Product in Canada
Nov 16, 2015
Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
Oct 30, 2015
Aequus Closes Financing for Gross Proceeds of C$1,237,500
Oct 21, 2015
Aequus Announces Terms of Public Offering of Common Shares
Oct 05, 2015
Aequus Announces Stock Option Grant
Oct 05, 2015
Aequus Announces Proposed Offering of Common Shares
Sep 30, 2015
Aequus Announces a Binding Term Sheet for the Marketing and Promotion of Transplant Products in Canadian Market
Aug 27, 2015
Aequus Pharmaceuticals Announces Trading on OTCQB
Jul 28, 2015
Aequus Pharmaceuticals Announces the Completion of the Acquisition of TeOra Health
Jul 23, 2015
Positive Preclinical Results and Patent Allowed for Aequus’ Once-Weekly Transdermal Aripiprazole
Jul 13, 2015
Aequus Pharmaceuticals Announces It Has Entered into a Definitive Agreement to Acquire TeOra Health and Intends to Promote Its First Commercial Product in Canada in 2015
May 28, 2015
Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
May 26, 2015
Aequus Retains Investor Relations Representative
Apr 28, 2015
Aequus and Corium Enter into Product Development Collaboration Focused on CNS
Mar 16, 2015
Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director
Mar 11, 2015
Aequus Pharmaceuticals Receives Conditional Approval To Commence Trading On TSX-V Exchange
Feb 20, 2015
Aequus Pharmaceuticals Becomes Reporting Issuer
Nov 20, 2014
Aequus Pharmaceuticals Closes $4.2 Million Private Placement Financing
May 27, 2014
Aequus Pharmaceuticals Announces Development Agreement for Transdermal Aripiprazole with Corium International
Sep 25, 2013
Aequus Pharmaceuticals Inc. closes on C$1.2 Million in equity financings, and in-licenses global rights to intellectual property enabling the transdermal delivery of aripiprazole
MORE TWEETS